Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boehringer Ingelheim and Eli Lilly and Co announce NDA filing in U.S. for combination tablet of Empagliflozin and Linagliptin


Monday, 14 Apr 2014 09:00am EDT 

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co:U.S. FDA accepted filing of NDA for investigational combination tablet of empagliflozin and linagliptin for treatment of adults with type 2 diabetes (T2D).This combination will bring together, for first time into one tablet, distinct mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.SGLT2 inhibitors remove excess glucose through urine by blocking glucose re-absorption in kidney.DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose. 

Company Quote

70.39
0.23 +0.33%
26 Dec 2014